CION Ameerpet
More than a third of breast cancers are diagnosed in women over 70 — and most are slow-growing, hormone-sensitive tumours that respond to gentler treatment. At CION Cancer Clinics in Hyderabad, our tumour board weighs your mother's age, fitness, heart and diabetes history before choosing surgery, hormone therapy or radiation. No rushed decisions. No over-treatment. A plan built around the life she wants to keep living.
Breast cancer is largely a disease of older age. Globally, more than half of all breast cancers are diagnosed after 60, and over a third of invasive breast cancers occur in women aged 70 and above. In India, older women often present later than they should — partly because routine breast cancer screening tapers off after 65, and partly because a new lump is wrongly dismissed as "just part of ageing."
The encouraging news is biology. In women over 70, roughly 80-90% of breast tumours are hormone-receptor (ER) positive — a slower-growing type that responds well to tablets, not just surgery and chemotherapy. That single fact reshapes the whole treatment plan. The goal in older women is rarely the most aggressive treatment; it is the right-sized one.
Over a third of invasive breast cancers are diagnosed in women aged 70+; risk keeps rising with age, so a new lump after 60 should always be checked, never dismissed.
80-90% of tumours in older women are ER-positive and slow-growing — which is exactly why gentler, tablet-based treatment often works as well as aggressive treatment.
Older Indian women often reach the clinic at a more advanced stage because screening stops and symptoms are ignored. Earlier action keeps gentler options open.
In women over 70, roughly 80-90% of breast tumours are hormone-receptor (ER) positive — a slow-growing type that often responds beautifully to a daily tablet rather than aggressive treatment. This favourable biology is why over-treatment, not under-treatment, is frequently the bigger risk for older women. Source: SEER and NCCN breast-cancer-in-older-adults data.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
The warning signs of breast cancer do not change with age — but the temptation to ignore them does. After 60, a painless lump, skin or nipple change is sometimes brushed off. It shouldn't be. Most of these cancers are slow-growing and very treatable when caught early, and catching them early is what keeps the gentle, low-side-effect options on the table.
See a doctor promptly if an older woman in your family notices any of the following. A clinical breast exam and a mammogram are simple, low-risk tests — there is no age at which they stop being worthwhile if treatment would still be considered.
Most often painless. In the breast or armpit. Any new, firm lump after 60 deserves a clinical exam and a mammogram — do not wait to "see if it goes away."
Inward-turning nipple, discharge (especially blood-stained), dimpling, puckering, redness or an orange-peel texture of the skin.
One breast becoming visibly larger, lower or differently shaped than before, or persistent swelling that does not settle.
Treating an 80-year-old with diabetes and a heart condition is not the same as treating a fit 50-year-old — and it should never be treated the same. CION was built around the idea that the plan should fit the patient. For older women, that means weighing how much benefit a treatment truly adds against what it costs her in energy, hospital visits and quality of life.
Our doctors are rewarded for outcomes, not for billing more procedures. That is why over-treatment — the real risk for elderly patients elsewhere — is something our tumour board actively guards against.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Free first consultation for every cancer patient. Clear costs, gentler options, and decisions made for healing, not billing.
The most important decision in elderly breast cancer is not which treatment, but how much. Three things guide that call, and we weigh all three together at the tumour board: the woman's overall fitness and life expectancy, her other health conditions, and the biology of her specific tumour (how fast it grows, whether it is hormone-sensitive, its stage).
A fit, independent 75-year-old with a slow ER-positive tumour and many good years ahead may benefit from full treatment. A frail 82-year-old with heart disease and a tiny, slow tumour may live just as long and far more comfortably on hormone tablets alone. "Watchful" never means "do nothing" — it means active monitoring with treatment held in reserve, started the moment it adds real benefit. Age alone is never the deciding factor; fitness and tumour biology are.
We use geriatric assessment (the G8 screen and a fuller Comprehensive Geriatric Assessment where needed) to measure mobility, nutrition, memory, other illnesses and support at home — a far better guide than age.
A small, hormone-sensitive, slow-growing tumour invites a gentler plan. A larger, fast-growing or triple-negative tumour in a fit woman calls for more active treatment.
If a treatment only pays off after 10 years and other health conditions make that unlikely, its benefit may not justify the burden. We are honest about this trade-off.
Skipping treatment purely because of age can shorten life and cause avoidable suffering. Fit older women deserve full, effective treatment — we guard against both extremes.
One of the biggest fears families bring to us is anaesthesia — "Is she too old for an operation?" In most cases, the honest answer is no. With modern surgery and anaesthesia, breast operations are considered safe in older women, with very low complication rates whether it is a lumpectomy (breast-conserving surgery) or a mastectomy. In one study of women aged 70+, there were low-to-moderate adverse events and no deaths within 30 days of surgery.
What makes surgery safe in an older patient is not avoiding it — it is preparing properly for it. Our anaesthesia and surgical teams assess frailty and fitness before the operation, optimise diabetes, blood pressure and heart conditions, and choose the least invasive approach that still does the job. Many older women go home the same day or the next day after a lumpectomy.
A frailty score and geriatric review before any operation predict and prevent complications. We fix what we can — anaemia, sugar, blood pressure — before the day of surgery.
Where the tumour allows, breast-conserving surgery with a sentinel node biopsy avoids the bigger operation and the longer recovery of a full mastectomy and node clearance.
For some frail patients, smaller procedures can be done under regional or local anaesthesia, reducing the risks of general anaesthesia altogether.
Day-care or single-night stays for many lumpectomies. Less time in hospital means less confusion, fewer infections and a quicker return to her own home and routine.
Because most tumours in older women are hormone-sensitive, two gentler, well-studied options often deliver the same result with far less burden than full treatment. These are not short-cuts — they are backed by large international trials and reflected in NCCN and global guidelines. The art is knowing exactly which woman they suit.
Hormone (endocrine) therapy alone — a daily tablet such as letrozole, anastrozole or tamoxifen — can control hormone-sensitive breast cancer in women who are unfit for surgery, or who choose to avoid it. Shorter radiation has transformed the schedule too: the FAST-Forward trial showed that 5 days of radiation works as well as the older 3-week course for many patients. And for some women over 70 with small, hormone-positive tumours treated by lumpectomy and hormone tablets, the landmark CALGB 9343 trial found that radiation can be safely skipped — it slightly reduced local recurrence but did not change survival.
For women unfit for surgery or who decline it, primary endocrine therapy (letrozole, anastrozole or tamoxifen) can control hormone-sensitive disease for years with a single daily tablet and simple monitoring.
Where radiation is needed, 5 daily sessions over a week are as effective as the older 3-week course for many patients — fewer trips to hospital, less fatigue, same control.
In selected women 70+ with small ER-positive tumours after lumpectomy and hormone tablets, radiation can be omitted with no loss of survival. We discuss this option openly when it applies.
Many older women with hormone-sensitive cancer gain little from chemotherapy. We reserve it for tumours and fitness levels where the benefit is real, with careful dose adjustment and monitoring.
Few older women come to us with cancer alone. Diabetes, high blood pressure, heart disease, kidney issues, arthritis and memory problems all change what treatment is safe and sensible. The mistake is to treat the cancer in isolation. At CION, the tumour board treats the whole person — and that means coordinating with the conditions she already lives with.
A heart condition may steer us away from certain chemotherapy drugs that affect the heart. Diabetes affects healing and infection risk, so we stabilise sugars before surgery. Kidney function guides drug doses. This careful coordination is exactly why a multidisciplinary team — not a single oncologist working alone — gives older patients the safest path.
Some chemotherapy and targeted drugs can strain the heart. For women with existing heart disease, we choose alternatives and monitor cardiac function throughout treatment.
Well-controlled sugars heal faster and resist infection. We optimise diabetes before surgery and watch for interactions with cancer medicines, especially steroids used during chemotherapy.
Drug doses are adjusted to kidney and liver function, which naturally decline with age — preventing the toxicity that comes from one-size-fits-all dosing.
Older patients are often on many tablets. We review the full medication list to avoid dangerous interactions and to keep the treatment plan as simple as possible.
For an older woman, the measure of good treatment is not only how long she lives, but how well. Independence, energy, time at home and freedom from unnecessary hospital trips often matter as much as a few extra months. We say this plainly because honesty is part of care: the most aggressive option is not always the kindest one.
Family is central to these decisions in Indian homes — in most cases a daughter, son or spouse is closely involved. We welcome that. But the patient's own wishes come first. Our role is to give the whole family clear, jargon-free information so the decision is truly shared: what each option offers, what it costs in side-effects and time, and what happens if you choose to do less. There are no wrong questions in a 45-minute consultation.
Here is how care for an older woman unfolds at CION — a clear, unrushed pathway from first visit to follow-up, designed to keep treatment proportionate at every step.
Our outcomes speak to this approach. CION's 1-year breast cancer survival is 96.9%, against the national average of 85.4% — an advantage of +11.5 percentage points.* That gap comes from getting the plan right: enough treatment to be effective, never so much that it harms a fragile patient. Your first 45-minute consultation is free — bring her reports and her family.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
We review her biopsy, scans, fitness and other conditions, then present the case to the full tumour board — surgical, medical and radiation oncologists deciding together.
In a 45-minute consultation we explain every option, the gentler alternatives, the trade-offs and the costs — so the family can make a truly informed, shared choice.
Surgery, hormone tablets, 1-week radiation or active monitoring — matched to her fitness and tumour, with care delivered close to home across 35+ centres.
Ongoing monitoring, side-effect management, nutrition and emotional support — with the plan adjusted as her health and wishes change over time.
Daughters and sons across Hyderabad have trusted CION with their mothers' breast cancer treatment in Hyderabad. Here is what they say about being heard, never rushed, and never over-treated.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.No. There is no upper age limit for breast cancer treatment. What matters is her overall fitness, other health conditions and the type of tumour — not her birth year. Many women in their 70s and 80s are treated safely and live many more good years. For fit older women, full treatment can add real survival benefit, while for frailer patients gentler options like hormone tablets give excellent control with little burden. At CION, our tumour board assesses fitness using a geriatric review and then matches the treatment to the woman, never the other way round. Book a free consultation and we will give you an honest answer for her specific situation.
Often, yes. Because around 80-90% of breast tumours in older women are hormone-sensitive (ER-positive), a daily hormone tablet such as letrozole, anastrozole or tamoxifen can control the cancer for years. This primary endocrine therapy is a recognised, evidence-based option for women who are unfit for surgery or who choose to avoid it. It is not a lesser treatment — for the right patient it controls disease with minimal side-effects and no hospital stay. Surgery still offers the best local control for fit patients, so we discuss both honestly. Our specialists explain which path suits your mother based on her tumour and fitness.
In most cases, yes. Modern breast surgery and anaesthesia are safe in older patients, with very low complication rates and studies showing no deaths within 30 days of surgery in women aged 70 and above. The key is preparation: we assess frailty, stabilise diabetes and blood pressure, and optimise any heart condition before the operation. Where suitable, we use breast-conserving surgery and, for some frail patients, regional or local anaesthesia to reduce risk further. Many older women go home the same day or the next after a lumpectomy. Our anaesthesia and surgical teams plan each case individually.
Not always. For selected women over 70 with small, hormone-positive tumours who have had a lumpectomy and take hormone tablets, the landmark CALGB 9343 trial showed that radiation can be safely skipped — it slightly reduced local recurrence but made no difference to survival. When radiation is needed, it no longer means weeks of daily trips: the FAST-Forward trial confirmed that just 5 days of radiation works as well as the older 3-week course for many patients. We discuss whether radiation adds real benefit for your mother, and if so, we use the shortest effective schedule to reduce fatigue and travel.
With age, a larger share of breast tumours are hormone-receptor (ER) positive — around 80-90% in women over 70. ER-positive cancers grow and spread more slowly than ER-negative or triple-negative types, because they depend on the hormone oestrogen to grow. This favourable biology is good news: it means slow, hormone-sensitive tumours often respond beautifully to tablets, and there is usually time to make a calm, considered decision rather than rushing into aggressive treatment. It does not mean the cancer can be ignored — early action keeps the gentlest options open — but it does mean over-treatment is rarely necessary.
Sometimes, but far less often than people expect. Most older women have hormone-sensitive cancer that responds to hormone tablets, and for these tumours chemotherapy frequently adds little benefit while causing significant side-effects. Chemotherapy is most useful for fit older women with faster-growing, hormone-negative or triple-negative tumours, or where the cancer has spread. When we do use it, doses are carefully adjusted for kidney, liver and heart function, with close monitoring. Our tumour board weighs the genuine benefit against the burden for each patient — we never give chemotherapy simply because it is available. Avoiding unnecessary chemo is part of good care for older women.
Through an honest, shared conversation — which is what our 45-minute consultation is built for. We explain every option, the gentler alternatives, what each costs in side-effects and hospital time, and what happens if you choose to do less. In Indian families a daughter, son or spouse is usually closely involved, and we welcome that — but the patient's own wishes come first. We help you weigh what matters most to her: more time, more independence, fewer hospital trips, comfort and dignity. There are no wrong questions. Bring her reports and the family, and we will guide the decision together.
Your first 45-minute consultation is completely free for every cancer patient. Bring her biopsy report, mammogram and any scans, along with a list of her current medicines and other health conditions. A specialist will review everything, examine her, and explain the likely options in plain language — including the gentler ones. Complex cases are then presented to our full tumour board of surgical, medical and radiation oncologists, so you get a team's opinion rather than one doctor's. We also explain costs transparently upfront. You can book at any of our 35+ centres across Telangana and Andhra Pradesh, or call us on 1800-202-8726.